Theravance Biopharma, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
George Town, Grand Cayman, CA
SEC filing record 1 source field available
Fiscal year end
31 December
Theravance Biopharma, Inc. has filed 1,125 SEC EDGAR filings since 01 Aug 2013

SEC filing history

Showing 876-900 of 1,000 matching filings.

Per page
25
Current page
36
S-3ASR File 333-214257

S-3ASR

Filing date
26 Oct 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
25 Oct 2016
Reporting date
25 Oct 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
20 Oct 2016
Reporting date
20 Oct 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
CT ORDER File 001-36033

CT ORDER filing

Filing date
11 Oct 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
04 Oct 2016
Reporting date
29 Sep 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
07 Sep 2016
Reporting date
07 Sep 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
25 Aug 2016
Reporting date
25 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
23 Aug 2016
Reporting date
20 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
23 Aug 2016
Reporting date
20 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
23 Aug 2016
Reporting date
20 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
23 Aug 2016
Reporting date
20 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
23 Aug 2016
Reporting date
19 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
23 Aug 2016
Reporting date
20 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
22 Aug 2016
Reporting date
18 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

THERAVANCE BIOPHARMA 8-K

Filing date
08 Aug 2016
Reporting date
08 Aug 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-88552

AMENDMENT NO. 2 SCHEDULE 13G

Filing date
04 Aug 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36033

8-K

Filing date
14 Jun 2016
Reporting date
08 Jun 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 May 2016
Reporting date
20 May 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 May 2016
Reporting date
20 May 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 May 2016
Reporting date
20 May 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 May 2016
Reporting date
20 May 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 May 2016
Reporting date
20 May 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 -

Filing date
24 May 2016
Reporting date
20 May 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .